Stocks Up as Bullar...
Health Care: Drugs
Synageva BioPharma Corp (GEVA: NASDAQ)
$39.52 0.73 | 1.88%
05/21/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -42.95M | -25.31M | 19.95M | 12.30M |
| Operating Gains/Losses | 0.00 | 0.00 | 359.00K | -61.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -388.00K | 1.59M | 7.00K | 411.00K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 1.07M | 1.08M | 0.00 | -325.00K |
| (Decrease) Increase In Other Current Liabilities | 109.00K | 1.85M | -6.24M | 2.87M |
| (Increase) Decrease In Other Working Capital | 2.65M | 2.74M | 935.00K | 421.00K |
| Other Non-Cash Items | 5.32M | 891.26K | -17.64M | 1.61M |
| Net Cash From Continuing Operations | -30.94M | -16.59M | -2.49M | 17.54M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -30.94M | -16.59M | -2.49M | 17.54M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 23.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 1.02M | 16.33M |
| Purchases of Property, Plant & Equipment | -394.00K | -682.92K | -781.00K | -855.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -195.36M | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | -3.75M | 50.11M | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -199.50M | 49.42M | 238.00K | 15.50M |
| Issuance of Debt | 0.00 | 12.50M | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 194.10M | 186.18K | 0.00 | 0.00 |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 194.10M | 12.69M | 0.00 | 0.00 |
| Effect of Exchange Rate Changes | -6.00K | -4.05K | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -36.35M | 45.52M | -2.26M | 33.03M |
Portfolios with GEVA
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks At New 52-Week Highs...
- ContributorStocks At New 52-Week Highs...
Latest GEVA Headlines from TheStreet
- Synageva BioPharma Corp Enters Oversold Territory (GEVA) 05.10.13 | 12:05 pm
- GEVA Crosses Below Key Moving Average Level 05.01.13 | 11:05 am
- Top Insider Trades: AEGR GEVA DRI HNSN 01.16.13 | 09:01 am
- 5 Stocks Insiders are Scooping Up 01.09.13 | 12:01 pm
- Top Insider Trades: NCR PLCE GEVA LEI 01.09.13 | 09:01 am
- 5 Stocks Insiders Love Right Now 07.18.12 | 10:07 am
- Insiders Trading GEVA, GNOM, VPRT, HSON 07.16.12 | 09:07 am
- Insiders Trading DNKN, GEVA, HMPR, PGCG 06.29.12 | 09:06 am
- Biotech Stock Mailbag: Exelixis, Protalix, Arena 05.04.12 | 07:05 am
- 8 Stocks Rising on Monster Volume 02.29.12 | 03:02 pm
Press Releases for GEVA
- Late Onset LAL Deficiency (CESD) Literature Review Published In The Journal Of Hepatology - Business Wire 03.26.13 | 07:03 am
- Synageva BioPharma™ Reports 2012 Full Year Financial Results - Business Wire 03.11.13 | 04:03 pm
- Synageva BioPharma™ To Host 2012 Fourth Quarter And Full Year Financial Results Conference Call On March 11 - Business Wire 03.01.13 | 12:03 pm
- Synageva BioPharma™ Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2013 - Business Wire 02.28.13 | 06:02 am
- Synageva BioPharma™ To Present At The Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.26.13 | 11:02 am
- Synageva BioPharma™ Initiates Dosing In Phase 3 Trial Of Sebelipase Alfa In Children And Adults With Late Onset LAL Deficiency - Business Wire 02.11.13 | 07:02 am
- Synageva BioPharma™ To Present At The Leerink Swann Global Healthcare Conference 2013 - Business Wire 02.06.13 | 04:02 pm
- Hepatology Publishes 12-Week Phase I/II Extension Study Data Of Sebelipase Alfa In Adults With Late Onset LAL Deficiency - Business Wire 02.04.13 | 04:02 pm
- Synageva BioPharma™ Highlights Data Presentations At The 9th Annual Lysosomal Disease Network (LDN) WORLD Symposium - Business Wire 01.30.13 | 04:01 pm
- Synageva BioPharma Announces Closing Of Public Offering And Exercise Of Option To Purchase Additional Shares - Business Wire 01.09.13 | 09:01 am
Partner Headlines for GEVA
- UPDATE: Piper Jaffray Lifts Synageva PT on Attractive Upcoming LAL-D Treatment - Benzinga 03.12.13 | 09:03 am
- UPDATE: Wedbush Securities Reiterates Outperform Rating, Raises PT on Synageva BioPharma Corp. - Benzinga 11.07.12 | 08:11 am
- Winning Trades Based on Analyst Ratings for June 25 - Benzinga 06.25.12 | 01:06 pm
- UPDATE: Morgan Stanley Initiates Synageva Biopharma with Buy, $76 PT - Benzinga 04.20.12 | 09:04 am
